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OBJECTIVE—The protein tyrosine phosphatase PTP1B is a
negative regulator of insulin signaling; consequently, mice deﬁ-
cient in PTP1B are hypersensitive to insulin. Because PTP1B
/
mice have diminished fat stores, the extent to which PTP1B
directly regulates glucose homeostasis is unclear. Previously, we
showed that brain-speciﬁc PTP1B
/ mice are protected against
high-fat diet–induced obesity and glucose intolerance, whereas
muscle-speciﬁc PTP1B
/ mice have increased insulin sensitivity
independent of changes in adiposity. Here we studied the role of
liver PTP1B in glucose homeostasis and lipid metabolism.
RESEARCH DESIGN AND METHODS—We analyzed body
mass/adiposity, insulin sensitivity, glucose tolerance, and lipid
metabolism in liver-speciﬁc PTP1B
/ and PTP1Bﬂ/ﬂ control
mice, fed a chow or high-fat diet.
RESULTS—Compared with normal littermates, liver-speciﬁc
PTP1B
/ mice exhibit improved glucose homeostasis and lipid
proﬁles, independent of changes in adiposity. Liver-speciﬁc
PTP1B
/ mice have increased hepatic insulin signaling, de-
creased expression of gluconeogenic genes PEPCK and G-6-
Pase, enhanced insulin-induced suppression of hepatic glucose
production, and improved glucose tolerance. Liver-speciﬁc
PTP1B
/ mice exhibit decreased triglyceride and cholesterol
levels and diminished expression of lipogenic genes SREBPs,
FAS, and ACC. Liver-speciﬁc PTP1B deletion also protects
against high-fat diet–induced endoplasmic reticulum stress re-
sponse in vivo, as evidenced by decreased phosphorylation of
p38MAPK, JNK, PERK, and eIF2 and lower expression of the
transcription factors C/EBP homologous protein and spliced X
box-binding protein 1.
CONCLUSIONS—Liver PTP1B plays an important role in glu-
cose and lipid metabolism, independent of alterations in adipos-
ity. Inhibition of PTP1B in peripheral tissues may be useful for
the treatment of metabolic syndrome and reduction of cardio-
vascular risk in addition to diabetes. Diabetes 58:590–599,
2009
I
n response to nutrients, insulin is secreted from
pancreatic -cells directly into the portal circulation,
where it promotes the storage of energy in the fed
state and is the major regulator of glucose ho-
meostasis (1,2). Insulin affects many components of he-
patic carbohydrate and lipid metabolism, including
glycogen synthesis, lipogenesis, and gluconeogenesis.
These effects are achieved by modiﬁcation of key molec-
ular targets, either by reversible phosphorylation or by
alteration of gene expression. Insulin promotes the ex-
pression of genes encoding glycolytic and lipogenic en-
zymes and suppresses genes encoding gluconeogenic
enzymes (3).
Insulin action is mediated by insulin receptors (IRs) on
the plasma membranes of responsive cells (4). Activation
of the IRs leads to transphosphorylation of tyrosine resi-
dues in the IR activation loop, which in turn leads to the
enhanced ability of the IRs to phosphorylate target pro-
teins, such as insulin receptor substrates (IRSs). Tyrosyl
phosphorylated IRS proteins act as docking sites for
several SH2 domain-containing proteins, including the p85
regulatory subunit of phosphatidylinositol 3-kinase. Phos-
phatidylinositol 3-kinase becomes activated upon binding
to IRS proteins, and its phosphoinositide products facili-
tate the activation of downstream targets.
Metabolic syndrome, type 2 diabetes, and cardiovascu-
lar disease are complex disorders that are associated with
obesity, aging, sedentary lifestyle, and genetic predisposi-
tion. A common feature of these disorders is the develop-
ment of insulin resistance, resulting in decreased insulin-
stimulated glucose uptake, failure to suppress hepatic
glucose production, and accumulation of hepatic lipid.
Although the detailed mechanism(s) underlying insulin
resistance remain controversial (4–7), there is general
agreement that impaired post-IR signaling is involved (8).
Recent data suggest that prolonged high-fat feeding in
mice leads to increased endoplasmic reticulum (ER) stress
in liver and adipose tissue and contributes to the develop-
ment of insulin resistance (9). The ER is a site of secretory
and membrane protein synthesis and modiﬁcation (10).
Upon disruption in either protein folding or modiﬁcation
within the ER, the unfolded protein response (UPR) is
activated. The unfolded protein response activates signal-
ing through three stress-sensing proteins found on the ER
membrane: PKR-like eukaryotic initiation factor 2 kinase
(PERK), inositol-requiring kinase-1 (IRE-1), and activat-
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590 DIABETES, VOL. 58, MARCH 2009ing transcription factor-6 (ATF-6) (11,12). The main pur-
pose of the UPR is to counter the deleterious effects of ER
stress, since prolongation of the ER stress response leads
to apoptosis, inﬂammation, and hepatic lipid accumulation
(13).
Whole-body knockout studies of protein tyrosine phos-
phatase 1B (PTP1B) in mice established PTP1B as a key
regulator of body mass and insulin sensitivity (14,15).
PTP1B
/ mice are lean because of enhanced leptin
sensitivity, are more insulin sensitive, and have enhanced
muscle and liver IR phosphorylation. In addition,
PTP1B
/ primary and immortalized ﬁbroblasts exhibit
decreased ER stress response through impaired IRE1
signaling, but the in vivo relevance of these observations is
not clear (16).
We recently generated tissue-speciﬁc PTP1B
/ mice
and found the brain to be the primary site mediating the
effects of PTP1B on body mass. Because mice with global
PTP1B deﬁciency and brain-speciﬁc PTP1B
/ mice are
lean, and leanness improves insulin sensitivity, it has been
difﬁcult to assess the direct role of PTP1B in insulin
sensitivity. Furthermore, recent studies have implicated a
brain-liver circuit in regulating insulin sensitivity, raising
the possibility that peripheral insulin sensitivity may be
mediated partly via neuronal circuits (17). Indeed, young
female brain-speciﬁc PTP1B
/ mice are more insulin
sensitive than controls, despite having comparable body
weight (18).
These studies raised the possibility that all of the insulin
sensitivity seen in PTP1B
/ mice might be due to central
effects. To begin to address this issue, we generated
muscle-speciﬁc PTP1B
/ mice and found that, compared
with controls, these mice exhibit signiﬁcant improvement
in whole-body glucose homeostasis on both chow and
high-fat diet (HFD) despite comparable body weight and
adiposity (19). In light of the critical role of the liver in
glucose homeostasis and the pathogenesis of diabetes
(5,13), and the potential role of PTP1B in the ER stress
response (16), we asked whether PTP1B also has auton-
omous effects on hepatic control of glucose homeosta-
sis and lipid metabolism by generating liver-speciﬁc
PTP1B
/ mice.
RESEARCH DESIGN AND METHODS
Animal studies. PTP1B ﬂoxed mice were generated previously (18). Alb-Cre
mice on a 129Sv/C57Bl6 hybrid background were obtained from C. Ronald
Kahn (Joslin Diabetes Center). All mice studied were age-matched littermate
males on the mixed 129Sv/C57Bl6 background. Mice were maintained in a
temperature-controlled barrier facility on a 12-h light/dark cycle with free
access to water and food (19). Genotyping for the PTP1B ﬂoxed allele and the
presence of Cre was performed by PCR (18).
Body composition. Mice were placed on standard lab chow or HFD at
weaning (21 days old), and weights were monitored weekly. Length was
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FIG. 1. Liver-speciﬁc PTP1B deletion has no effect on body weight or adiposity. A: Deletion efﬁciency, as detected by PCR and Western blotting,
in the indicated tissues from Alb-Cre-PTP1B
/ and ﬂ/ﬂ littermates. PCR was performed on DNA isolated from Alb-Cre-PTP1B
/ tissues: P,
pituitary; B, brain; L, liver; M, gastrocnemius muscle; S, spleen; H, heart; W, abdominal white adipose tissue; K, kidney; and L, lung. “” and “”
represent negative and positive controls, respectively. The immunoblot in the lower panel indicates 80% deletion of PTP1B protein in liver,
consistent with deletion from hepatocytes, which comprise that approximate percentage of the liver. B: Weight curves for Alb-Cre-PTP1B
/ (n 
6) and Alb-Cre-PTP1B
/ mice (n  10) vs. ﬂ/ﬂ controls (n  16) on chow diet from weaning to 17 weeks of age (left). Weight curves for
Alb-Cre-PTP1B
/ (n  12) and ﬂ/ﬂ controls (n  12) on HFD from weaning to 19 weeks of age (right). C: Fat pad weights of 19-week-old
Alb-Cre-PTP1B
/ (n  12) and Alb-Cre-PTP1B
/ (n  9) vs. ﬂ/ﬂ mice (n  12) on HFD. BAT, brown adipose tissue; EPI, epididymal; MES,
mesenteric; RP, retroperitoneal; and SUB Q, subcutaneous. D: Leptin levels (ng/ml) in Alb-Cre-PTP1B
/ (n  5) and ﬂ/ﬂ mice (n  9) on chow
diet and Alb-Cre-PTP1B
/ (n  10) and ﬂ/ﬂ mice (n  12) on HFD (at 5 months of age). E: Length (cm) of Alb-Cre-PTP1B
/ (n  12) and
PTP1B
/ (n  9) vs. ﬂ/ﬂ mice (n  12) on HFD.
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HFD for 18 weeks and weighed individually (19).
Metabolic measurements. Glucose in tail blood was assayed using a
glucometer (Lifescan). Fed measurements were taken between 8:00 and 10:00
A.M. and, where indicated, from mice fasted for 12 h. Serum insulin and leptin
were determined by ELISA (CrystalChem), and free fatty acids were quantiﬁed
by enzymatic assay (Wako). Insulin tolerance tests (ITTs) and glucose
tolerance tests (GTTs) were performed as described (18,19). A 2-h hyperin-
sulinemic-euglycemic clamp was conducted in awake Alb-Cre-PTP1B
/ mice
(n  15) and ﬂ/ﬂ littermates (n  13) at a continuous insulin infusion rate of
2.5 mU  kg
1  min
1, as described previously (19 and in the supplemental
information, found in an online-only appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-0913/DC1).
Biochemical studies. For insulin signaling experiments, animals were fasted
for 12 h, saline or insulin (10 mU/g) was injected intraperitoneally, and livers
were removed 10 min later. Mouse tissues were dissected and frozen in liquid
N2. Tissue lysates were prepared by extraction in radioimmunoprecipitation
assay (RIPA) buffer at 4°C, followed by clariﬁcation at 14,000g (19,20). For
immunoblots, proteins were resolved by SDS-PAGE and transferred to PVDF.
Immunoblots were performed with polyclonal antibodies against pIR1162/
1163 (Invitrogen), IR (Santa Cruz), IRS-1/IRS-2 (Millipore), p85 (Millipore),
phospho-GS-Ser641 (Cell Signaling), glycogen synthase chicken antibody (gift
from the late Dr. John Lawrence, UVA), or PTP1B (Millipore). For ER stress
experiments, the following antibodies, all from Cell Signaling, were used:
p-p38, p38, pJNK, pPERK, peIF2a (Ser 51), and eIF2. Proteins were visualized
using enhanced chemiluminescence and quantiﬁed by scanning densitometry
(Image J software). Phosphorylated IRS-1 in livers (2 g protein) was detected
by enzyme-linked immunosorbent assay (ELISA) (PathScan Phospho-IRS-1,
Cell Signaling). For immunoprecipitation studies, IRS-1 or IRS-2 was immu-
noprecipitated from liver lysates (1 mg) with IRS-1 (Millipore) or IRS-2
antibody (Santa Cruz) and protein A Sepharose. Immunoprecipitates were
washed four times with lysis buffer, subjected to SDS-PAGE, transferred to
PVDF membranes, and immunoblotted with anti-phosphotyrosine antibody
(Santa Cruz) or p85 antibody (Millipore). No differences in total IRS-1 or IRS-2
levels were detected.
Gene expression analysis. Liver RNA was isolated using Trizol (Invitrogen)
and puriﬁed with the RNeasy kit (Qiagen). A total of 1 g RNA was
reverse-transcribed in 20 l reaction volume with the Advantage RT-for-PCR
kit (Clontech). Then 1–2 l cDNA was used to amplify the target genes in the
real-time RT-PCR (20 l) using SYBR Green PCR Master Mix (ABI) followed
by analysis using the Eppendorf Mastercycler ep Realplex. Relative gene
expression was calculated using the comparative Ct (2
Ct) method. The
relative copy number of GAPDH and 18S was used for normalization (SABio-
sciences RT
2 qPCR Primer Assays). PCRs were followed by melting curve
(60–95°C) and agarose gel analysis to ensure speciﬁcity (for primer sequences
and PCR conditions, see the supplemental information).
Lipid analysis. Serum and liver triglycerides and cholesterol were measured
at the Vanderbilt MMPC Lipid Core facility. Lipids were extracted using the
method of Folch et al. (21), and individual lipid classes were separated by
thin-layer chromatography and visualized by rhodamine 6G. Triglycerides
were quantiﬁed as described (22). Cholesterol measurements were performed
by gas chromatography as described (23).
RESULTS
Generation of liver-speciﬁc PTP1B
/ mice. Mice with
liver-speciﬁc PTP1B deletion were generated by crossing
PTP1Bﬂ/ﬂ mice to mice expressing Cre recombinase under
the control of the albumin promoter (Alb-Cre). The result-
ant Alb-Cre PTP1B /ﬂ mice were crossed to PTP1Bﬂ/ﬂ
mice, yielding Alb-Cre PTP1Bﬂ/ﬂ mice (hereafter termed
Alb-Cre-PTP1B
/ mice), Alb-Cre PTP1B /ﬂ mice, and
PTP1Bﬂ/ﬂ controls (18). PCR for the deleted PTP1B allele
conﬁrmed that deletion occurred only in the liver (Fig. 1A,
top panel). As expected, Alb-Cre-PTP1B
/ mice exhibited
80% reduction in PTP1B protein in the liver (1), consis-
tent with hepatocyte-speciﬁc deletion. Other insulin-re-
sponsive tissues had normal levels of PTP1B protein (Fig.
1A, bottom panel).
Alb-Cre-PTP1B
/ and control mice were weaned onto
either HFD (55% kcal from fat) or normal chow (4.5% fat).
The absence of PTP1B in hepatocytes had no effect on
body weight on either diet (Fig. 1B), as expected from
previous studies (18). Adiposity, as assessed by fat pad
weights (Fig. 1C) and leptin levels (Fig. 1D), and length
(Fig. 1E), were unaffected by PTP1B deﬁciency. Hematox-
ylin and eosin staining of liver sections revealed no overt
histological differences between Alb-Cre-PTP1B
/ and
ﬂ/ﬂ control littermates (data not shown).
Improved glucose homeostasis in Alb-Cre-PTP1B
/
mice. Compared with littermate controls, Alb-Cre-
PTP1B
/ mice fed an HFD exhibited lower fed glucose
levels at 8 weeks of age and lower fasted glucose, serum
TABLE 1
Blood glucose, serum insulin, plasma free fatty acids, and liver glycogen were analyzed in male PTP1B ﬂ/ﬂ control and
Alb-Cre-PTP1B
/ mice (n  6–18 mice/group) fed chow or HFD as indicated
Chow HFD
PTP1B ﬂ/ﬂ (control) Alb-Cre-PTP1B
/ PTP1B ﬂ/ﬂ (control) Alb-Cre-PTP1B
/
Blood glucose (mg/dl)
Fasted 8 weeks 55.4 	 2.5 55.0 	 1.7 75.0 	 4.3 63.2 	 5.7
Fed 8 weeks 111.1 	 4.6 111.6 	 2.2 111.6 	 3.9 88.1 	 2.3*
Fasted 16 weeks 70.8 	 5.5 63.6 	 4.9 72.4 	 6.6 50.2 	 7.3†
Fed 16 weeks 103.7 	 4.6 94.8 	 3.3 121.2 	 5.5 110.5 	 7.3
Serum insulin (ng/ml)
Fed 8 weeks 0.64 	 0.10 0.64 	 0.08 1.30 	 0.31 1.06 	 0.15
Fed 16 weeks ND ND 5.11 	 1.11 2.35 	 0.24*
Pre-clamp (fasted) 0.20 	 0.05 0.13 	 0.02 ND ND
Clamp 0.93 	 0.18 0.72 	 0.18
GTT time 0 min 0.30 	 0.06 0.24 	 0.06
GTT time 15 min 0.59 	 0.08 0.73 	 0.08
GTT time 30 min 0.54 	 0.07 0.63 	 0.04
Plasma free fatty acids (mmol/l)
Fasted 16 weeks ND ND 0.885 	 0.075 0.942 	 0.079
Fed 16 weeks 0.456 	 0.047 0.413 	 0.067 0.523 	 0.041 0.483 	 0.065
Liver glycogen (g/mg)
Fasted ND ND 2.16 	 0.44 1.94 	 0.63
Fed 19.92 	 1.22 20.91 	 0.58
Data are means 	 SE and were analyzed by two-tailed Student’s t test. *P 
 0.01, †P 
0.05 for the indicated genotype compared with PTP1B
ﬂ/ﬂ control littermates. ND, not determined.
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of age, indicating an overall improvement in glucose
homeostasis (Table 1; Fig. 2A). Alb-Cre-PTP1B
/ mice
also exhibited an enhanced ability to clear glucose from
the peripheral circulation during intraperitoneal GTTs on
either chow (8 weeks of age) or HFD (11 weeks of age)
compared with controls (Fig. 2B and C). Insulin secretion
during the GTTs was similar in Alb-Cre-PTP1B
/ and ﬂ/ﬂ
controls (Table 1). In contrast to their improved GTTs,
ITTs were normal in Alb-Cre-PTP1B
/ mice (Fig. 2D and
E; see DISCUSSION).
Increased suppression of hepatic glucose production
in Alb-Cre-PTP1B
/ mice. To assess whether improved
glucose tolerance was due to autonomous effects of
PTP1B deﬁciency in the liver, we performed hyperinsu-
linemic-euglycemic clamps in male Alb-Cre-PTP1B
/ and
ﬂ/ﬂ control mice fed a chow diet. Hepatic glucose produc-
tion during the insulin-stimulated state (clamp) was
signiﬁcantly lower in Alb-Cre-PTP1B
/ mice (Fig. 3A),
resulting in 30% higher insulin-mediated suppression of
hepatic glucose production in Alb-Cre-PTP1B
/ mice
(Fig. 3B). Basal blood glucose levels in Alb-Cre-PTP1B
/
mice were similar to those in control littermates and were
maintained at levels comparable to those of controls
during the clamp (Fig. 3C). The glucose infusion rate
required to maintain euglycemia during clamps trended
higher in Alb-Cre-PTP1B
/ mice (P  0.052), indicating
an overall improvement in insulin sensitivity (Fig. 3D).
Insulin-stimulated whole-body glucose turnover and glu-
cose metabolism in skeletal muscle were similar between
the two groups (Fig. 3E–G). These data suggest that
improvement in whole-body glucose homeostasis, as mea-
sured by GTT in Alb-Cre-PTP1B
/ mice, is mostly due to
increased insulin sensitivity in liver.
Increased insulin signaling in liver lacking PTP1B. To
investigate the molecular mechanism of improved hepatic
insulin sensitivity in Alb-Cre-PTP1B
/ mice, we injected
fasted, male Alb-Cre-PTP1B
/, or ﬂ/ﬂ littermate control
mice with insulin or saline (control) and examined insulin
signaling in liver. We analyzed phosphorylation of Y1162/
Y1163 on the insulin receptor because these sites are
reported to be preferentially dephosphorylated by PTP1B
(24,25). Insulin-stimulated IR phosphorylation was higher
in Alb-Cre-PTP1B
/ mice on a chow diet compared with
controls (Fig. 4A). High-fat feeding blunted hepatic insulin
signaling in ﬂ/ﬂ mice, resulting in a less robust increase in
insulin-induced IR phosphorylation. However, insulin-in-
duced IR phosphorylation in Alb-Cre-PTP1B
/ liver was
greater than in control mice (Fig. 4B). Basal IRS-1 tyrosine
phosphorylation was increased in HFD-fed Alb-Cre-
PTP1B
/ mice (Fig. 4C). Insulin-stimulated IRS-1 phos-
phorylation tended to be higher in Alb-Cre-PTP1B
/
mice, although this did not reach statistical signiﬁcance. In
contrast, basal tyrosine phosphorylation of IRS-2 was
similar between the two groups, but insulin-stimulated
IRS-2 phosphorylation was elevated in HFD-fed Alb-Cre-
PTP1B
/ mice (Fig. 4D). Improved hepatic insulin signal-
ing was also evident downstream, since Alb-Cre-PTP1B
/
mice exhibited higher insulin-stimulated IRS-1 and IRS-2
p85 association than controls, as well as reduced phos-
phorylation of glycogen synthase (Fig. 4E). These bio-
chemical data suggest that the improved hepatic insulin
action in Alb-Cre-PTP1B
/ mice is the direct result of
increased IR signaling.
Insulin regulates hepatic glucose metabolism in part by
altering gene expression (8). Consistent with their im-
proved glucose homeostasis, the levels of peroxisome
proliferator–activated receptor- coactivator-1 (PGC-
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FIG. 2. Improved glucose homeostasis in Alb-Cre-PTP1B
/
mice. A: Insulin-to-glucose ratio in male Alb-Cre-PTP1B
/
(n  13), Alb-Cre PTP1B
/ (n  8), and ﬂ/ﬂ (n  14) mice on
HFD at 8 and 16 weeks of age, respectively. B: GTTs on male
Alb-Cre-PTP1B
/ (n  6), Alb-Cre PTP1B
/ (n  6), and ﬂ/ﬂ
control mice (n  8) on chow diet at 8 weeks of age. C: GTTs
on male Alb-Cre-PTP1B
/ (n  6), Alb-Cre PTP1B
/ (n  8),
and ﬂ/ﬂ mice (n  8) on HFD for 8 weeks (11 weeks of age).
D: ITTs on male Alb-Cre-PTP1B
/ (n  6), Alb-Cre PTP1B
/
(n  6), and ﬂ/ﬂ mice (n  8) on chow diet at 8 weeks of age
(insulin dose 0.75 mU/g). E: ITTs on male Alb-Cre-PTP1B
/
(n  6) and ﬂ/ﬂ mice (n  8) on HFD for 7 weeks (10 weeks
of age) (insulin dose 1 mU/g). Data were analyzed by two-way
ANOVA (*P < 0.05 for Alb-Cre-PTP1B
/ vs. ﬂ/ﬂ).
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glucose-6-phosphatase (G-6-Pase) mRNA were signiﬁ-
cantly lower in Alb-Cre-PTP1B
/ mice fed an HFD for 18
weeks compared with controls (Fig. 4F).
Improved lipid homeostasis in Alb-Cre-PTP1B
/
mice. Because the liver plays a major role in lipid metab-
olism, we assessed several parameters of whole-body lipid
homeostasis in Alb-Cre-PTP1B
/ and control mice. Se-
rum free fatty acids were unchanged between the two
groups of mice (Table 1). However, liver triglyceride levels
were signiﬁcantly lower in Alb-Cre-PTP1B
/ mice after 5
weeks of high-fat feeding (Fig. 5A), whereas this difference
was not detectable at 18 weeks of HFD, probably due to
very high levels of triglyceride at this time. Serum triglyc-
eride levels were also lower in Alb-Cre-PTP1B
/ mice fed
an HFD (Fig. 5B).
Lipid homeostasis in vertebrate cells is regulated by a
small family of membrane-bound transcription factors,
designated sterol regulatory element–binding proteins
(SREBPs), which directly activate the expression of 30
genes dedicated to the synthesis and uptake of choles-
terol, fatty acids, triglycerides, and phospholipids (26).
Analysis of the hepatic lipogenic genes SREBP1a and
SREBP1c, and their target genes fatty acid synthase (FAS)
and acetyl-CoA carboxylase (ACC), revealed a decrease in
their mRNA levels in HFD-fed Alb-Cre-PTP1B
/ mice
(Fig. 5C). Expression of genes involved in cholesterol
synthesis, such as SREBP2 and its target gene 3-hydroxy-
3-methylglutaryl-coenzyme A synthase 1 (HMGCS1), also
were signiﬁcantly decreased in HFD-fed Alb-Cre-
PTP1B
/ mice (Fig. 5D). Consistent with their reduced
SREBP2 and HMGCS1 expression, liver cholesterol levels
were signiﬁcantly lower in HFD-fed Alb-Cre-PTP1B
/
mice compared with controls (Fig. 5E). In fact, cholesterol
levels in Alb-Cre-PTP1B
/ mice fed an HFD were similar
to those measured in chow-fed mice (data not shown),
suggesting that liver-speciﬁc PTP1B deletion protects
against cholesterol accumulation caused by prolonged
HFD feeding. Serum cholesterol levels in HFD-fed Alb-Cre-
PTP1B
/ mice also were lower than in control littermates
(Fig. 5F).
Decreased ER stress response in HFD-fed Alb-Cre-
PTP1B
/ mice. Genetic and dietary obesity in mice
induce the ER stress response, which is associated with
insulin resistance and intracellular lipid accumulation (9).
To investigate whether deﬁciency of PTP1B in liver pro-
tects against HFD-induced ER stress, we analyzed compo-
nents of the ER stress response in livers of 18-week
HFD-fed Alb-Cre-PTP1B
/ and control mice. PTP1B
/
ﬁbroblasts reportedly have decreased phosphorylation of
stress-activated p38 MAPK (16). Likewise, Alb-Cre-
PTP1B
/ mice had decreased levels of p38 MAPK in their
livers, but in addition, JNK, pPERK, and eIF2 phosphor-
ylation was also reduced. Together, these data suggest that
Alb-Cre-PTP1B
/ mice are more resistant to HFD-in-
duced ER stress than controls (Fig. 6A and B). Consistent
with this notion, expression of the pro-apoptotic transcrip-
tion factor C/EBP homologous protein (CHOP), while
substantially induced by prolonged high-fat feeding in
control and Alb-Cre-PTP1B
/ mice, was signiﬁcantly
lower at the mRNA and protein level in PTP1B-deﬁcient
livers (Fig. 6C). As expected from in vitro studies (16),
expression of XBP1s (a key factor in ER stress) was also
reduced (Fig. 6D). Thus, mice lacking PTP1B in the liver
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an additional potential mechanism by which glucose and
lipid homeostasis after prolonged high-fat feeding is im-
proved in these mice.
DISCUSSION
Metabolic syndrome, which is associated with hyperinsu-
linemia, hyperglycemia, and lipid abnormalities, often
leads to diabetes and cardiovascular disease (27–29).
Insulin resistance plays a key role in the pathophysiology
of metabolic syndrome, resulting in decreased glucose
metabolism, insulin action, and alterations in hepatic lipid
metabolism. Whole-body knockout studies of mice
showed that PTP1B is a major regulator of insulin sensi-
tivity and body weight (14,15) and suggested that PTP1B
might be a useful target for the therapy of diabetes and
obesity. Here we found that mice lacking PTP1B selec-
tively in the liver have improved glucose homeostasis and
reduced levels of triglycerides and cholesterol, indepen-
dent of changes in body weight or adiposity. These studies
show that PTP1B has autonomous effects on both glucose
and lipid metabolism in the liver and extend the potential
utility of PTP1B inhibitors to the treatment of metabolic
syndrome.
The metabolic importance of hepatic insulin signaling
was validated by mice with liver-speciﬁc deletion of the IR
(LIRKO), which exhibit dramatic insulin resistance, severe
glucose intolerance, and dysregulated hepatic gene ex-
pression (1). Alb-Cre-PTP1B
/ mice exhibit increased
insulin-stimulated IR phosphorylation, as well as basal
IRS-1 and insulin-stimulated IRS-2 tyrosine phosphoryla-
tion. Increased insulin-stimulated IR phosphorylation in
these mice is in line with the known role of PTP1B as a
negative regulator of IR signaling (14,15), whereas the
elevation of basal IRS-1 tyrosine phosphorylation in Alb-
Cre-PTP1B
/ mice in the absence of increased basal IR
phosphorylation is consistent with previous studies show-
ing that PTP1B also can dephosphorylate IRS-1 directly in
vitro (30).
Insulin signaling suppresses gluconeogenic gene expres-
sion. Notably, IRS-1 and IRS-2 have complementary roles
in the liver, with IRS-1 more closely linked to glucose
homeostasis and IRS-2 more important for lipid metabo-
lism (31). Knockdown of IRS-1 in the livers of wild-type
mice results in upregulation of G-6-Pase and PEPCK.
Consistent with increased IR and IRS-1 tyrosine phosphor-
ylation, we observe decreased expression of G-6-Pase and
PEPCK in livers of Alb-Cre-PTP1B
/ mice. The PGC-1
promoter is activated by FoxO1 (32). Insulin suppresses
PGC-1 gene expression by promoting Akt phosphoryla-
tion and subsequent phosphorylation and nuclear exclu-
sion of FoxO1 (33). PGC-1 expression is elevated in livers
of insulin-resistant ob/ob and LIRKO mice, conﬁrming a
key role for insulin as a suppressor of PGC-1 in vivo
(34,35). As would be expected in a mouse model with
enhanced hepatic insulin sensitivity, we observe de-
creased expression levels of PGC-1 in livers of Alb-Cre-
PTP1B
/ mice.
Alb-Cre-PTP1B
/ mice show enhanced ability of insu-
lin to suppress hepatic glucose production and increased
hepatic insulin signaling. Alb-Cre-PTP1B
/ mice also
exhibit enhanced ability to clear glucose from the periph-
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FIG. 5. Improved lipid metabolism in Alb-Cre-PTP1B
/ mice. Liver triglycerides (A) or serum triglycerides (B) are shown for male
Alb-Cre-PTP1B
/ (n  8) and control (n  8) mice fed HFD for the indicated time in weeks. C and D: Relative mRNA levels, measured by
quantitative real-time PCR normalized against 18S mRNA, in livers from male Alb-Cre-PTP1B
/ (n  8) and ﬂ/ﬂ control mice (n  8) fed HFD
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/.
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596 DIABETES, VOL. 58, MARCH 2009eral circulation during GTTs; however, ITTs are similar
between Alb-Cre-PTP1B
/ and control mice. Muscle and
liver have different “set-points” for insulin action, with
higher doses required to stimulate glucose uptake into
muscle than to suppress hepatic glucose production. The
comparable ITTs in Alb-Cre-PTP1B
/ and control ani-
mals are probably due to the relatively high insulin doses
used for ITTs, which results in complete suppression of
hepatic glucose production.
In addition to its effects on glucose homeostasis, insulin
regulates hepatic lipid metabolism by altering lipogenic
gene transcription. High insulin levels persistently activate
SREBP1c transcription and cleavage, even after patients
become “insulin resistant” at the level of gluconeogenesis
(26). This leads to increased lipogenic gene expression
and accelerated triglyceride accumulation in the liver
(36–38). Conﬁrming the importance of the insulin receptor
in mediating these effects, LIRKO mice have low serum
triglyceride levels and decreased SREBP1c gene expres-
sion (29). LIRKO mice, however, also have 10-fold higher
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DIABETES, VOL. 58, MARCH 2009 597circulating leptin levels (39), and leptin has been sug-
gested to play a role in regulation of glucose homeostasis
(40) and plasma triglycerides (41). Surprisingly, SREBP1c
and SREBP1a gene expression levels are signiﬁcantly
lower in Alb-Cre-PTP1B
/ mice than in controls. This is
opposite to what would be expected from the LIRKO
phenotype and the enhanced insulin sensitivity seen in
Alb-Cre-PTP1B
/ mice. Consistent with their decreased
SREBP1 expression, expression of the SREBP target
genes FAS and acetyl-CoA carboxylase and serum triglyc-
eride levels are reduced in Alb-Cre-PTP1B
/ mice. Treat-
ment of ob/ob mice with PTP1B oligonucleotides resulted
in a similar decrease in lipogenic gene expression, includ-
ing SREBP1 (38). Furthermore, a study in which high-
fructose feeding was used to induce insulin resistance in
rats reported a direct association between increased
hepatic expression of SREBP1c and PTP1B and sug-
gested a novel mechanism by which PTP1B regulates
SREBP1c expression levels by enhancing PP2A activity
(43). We therefore suspect that PTP1B may affect SREBP1
gene expression via a pathway distinct from the insulin
signaling; however, further work is required to clarify the
precise mechanism.
Reduced expression of lipogenic genes in livers of
Alb-Cre-PTP1B
/ mice, as well as lower triglyceride, is
most likely the direct result of decreased levels of SREBP.
Although recent studies of LIRKO mice emphasize the
importance of insulin in regulating hepatic lipid balance,
for the reasons discussed above, the effects of hepatic
PTP1B deﬁciency on lipid homeostasis cannot be directly
attributed to improved insulin action. Previous studies
indicate that PTP1B also regulates growth hormone (GH)
signaling (44), and GH has been shown to normalize serum
triglyceride and cholesterol levels in aged rats (45). We
cannot exclude the possibility that hepatic GH signaling
may be altered in Alb-Cre-PTP1B
/ mice, although we did
not observe differences in linear growth between Alb-Cre-
PTP1B
/ and control mice.
Insulin resistance can lead to hepatic fat accumula-
tion, even in the absence of obesity, as evidenced by the
prevalence of nonalcoholic fatty liver disease in normal-
weight humans. Recent studies have shown that hepatic
cholesterol, rather than hepatic triglyceride, may play
an important role in the pathogenesis of nonalcoholic
fatty liver disease (46). Free cholesterol (but not free
fatty acids or triglyceride) accumulation in hepatocytes
sensitizes mice to TNF- or Fas-induced fatty liver (47).
LIRKO mice fed a high-fat “Western” diet (40% fat)
develop marked hypercholesterolemia, whereas con-
sumption of an atherogenic diet (15% fat, 1% cholesterol,
0.5% cholic acid) produces hypercholesterolemia and
severe atherosclerosis. Alb-Cre-PTP1B
/ mice have
lower expression of genes involved in cholesterol syn-
thesis, including SREBP2 and HMGCS1, as well as
decreased serum and liver cholesterol levels on a high-
fat diet. High-fat feeding increases PTP1B expression in
the liver (48), raising the intriguing possibility that
PTP1B deﬁciency/inhibition in the liver may protect
against the progression of fatty liver disease. How
liver-speciﬁc deﬁciency of PTP1B results in decreased
SREBP2 expression awaits further studies.
Recent studies demonstrated that HFD-feeding and ge-
netic obesity (ob/ob) in mice induces the ER stress re-
sponse (9), leading to cell death, inﬂammation, insulin
resistance, and intracellular lipid accumulation. PERK is
an ER transmembrane protein kinase that phosphorylates
the -subunit of eukaryotic translation initiation factor 2
(eIF2) in response to ER stress, and the phosphorylation
status of PERK and eIF2 is therefore a key indicator of
ER stress. Examination of downstream markers for ER
stress, such as CHOP (13), a b-ZIP transcription factor that
potentiates apoptosis (11), or spliced XPB1, which plays a
key role in the ER stress response by regulating the
transcription of an array of genes, provides an additional
readout of these ER stress pathways. Furthermore, ER
stress-evoked signaling downstream of IRE1 leads to
activation of p38 MAPK and c-Jun NH2-terminal kinase
(JNK) (9).
Studies performed on PTP1B
/ primary and immortal-
ized ﬁbroblasts revealed that the absence of PTP1B pro-
tects against ER stress response (16). We found that
Alb-Cre-PTP1B
/ livers are more resistant to HFD-in-
duced ER stress response. Phosphorylation of p38 was
signiﬁcantly lower in livers from Alb-Cre-PTP1B
/ mice
compared with controls, as was phosphorylation of JNK,
PERK, and eIF2, suggesting that liver PTP1B deﬁciency
causes impaired ER stress–induced IRE1 signaling. CHOP
and XBP1s levels also were decreased in HFD-fed Alb-Cre-
PTP1B
/ mice, consistent with impaired ER stress-in-
duced PERK signaling. These in vivo studies demonstrate
for the ﬁrst time that PTP1B deﬁciency affects multiple
“arms” of the ER stress response.
Overall, our ﬁndings demonstrate that PTP1B plays a
critical role in hepatic glucose and lipid metabolism.
Selective enhancement of insulin signaling in the liver
would normally be expected to suppress gluconeogen-
esis, while enhancing lipogenesis and fat accumulation
in the liver. Alb-Cre-PTP1B
/ mice represent a model
of “selective” insulin hypersensitivity, whereby glu-
coneogenic gene expression is suppressed and glucose
homeostasis is improved, whereas triglyceride and cho-
lesterol levels are improved as well. Our previous
studies showed that inhibiting neuronal PTP1B is criti-
cal for conferring the beneﬁcial effects of PTP1B deﬁ-
ciency on body mass/adiposity (18). Because of
technical limitations in designing speciﬁc, bioavailable
PTP1B inhibitors, the brain may be particularly difﬁcult
to target for therapy (49). The current results, combined
with our previous studies of muscle-speciﬁc PTP1B
/
mice (19), indicate that inhibiting PTP1B in the periph-
ery should result in improved insulin sensitivity. Fur-
thermore, inhibition of PTP1B in liver would have a
beneﬁcial lipid-lowering effect. Thus, PTP1B inhibitors
may be an attractive therapy for use in the treatment of
metabolic syndrome and cardiovascular risk, in addition
to insulin resistance and diabetes.
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